Research Article
Thin Strut CoCr Biodegradable Polymer Biolimus A9-Eluting Stents versus Thicker Strut Stainless Steel Biodegradable Polymer Biolimus A9-Eluting Stents: Two-Year Clinical Outcomes
Table 1
Baseline demographics and procedural details.
| | | CoCr-BP-BES n = 400 | SS-BP-BES n = 857 | value |
| | Baseline demographics | | Mean age (years) | 64.7 ± 11 | 64.6 ± 10.8 | 0.892 | | Female gender (%) | 21.5 | 25 | 0.178 | | STEMI or NSTEMI (%) | 41.1 | 32.7 | 0.004 | | Unstable angina (%) | 14 | 22.2 | <0.001 | | Prior MI (%) | 18.8 | 32.2 | <0.0001 | | Previous PCI or CABG (%) | 24.6 | 40.9 | <0.0001 | | Previous stroke (%) | 6.3 | 4.7 | 0.292 | | Current smoker (%) | 21 | 24.1 | 0.229 | | Hypertension (%) | 57.3 | 73.6 | <0.0001 | | Dyslipidemia (%) | 56.7 | 65.4 | 0.003 | | Diabetes (%) | 19.3 | 26.1 | 0.009 | | Renal insufficiency (%) | 11.5 | 5.4 | <0.0001 |
| | Procedural details | | Staged procedure (%) | 5.5 | 4.4 | 0.476 | | Target lesion coronary artery (%) | | | | | LAD | 47.4 | 37.2 | <0.0001 | | LCX | 20.1 | 28 | <0.001 | | LM | 2.3 | 2.6 | 0.399 | | RCA | 26.9 | 30.7 | 0.112 | | De novo lesions (%) | 95.9 | 94 | 0.123 | | Bifurcation lesions (%) | 25.8 | 22.4 | 0.132 | | Number of stents per lesion | 1.34 ± 0.70 | 1.20 ± 0.48 | <0.0001 | | Severe calcification (%) | 16.2 | 13.1 | 0.09 | | Lesion length (mm) | 21.7 ± 12.8 | 15.2 ± 11.7 | <0.0001 | | Reference vessel diameter (mm) | 3.0 ± 0.5 | 2.6 ± 0.61 | <0.0001 |
|
|
CABG=coronary artery bypass grafting, CoCr-BP-BES = cobalt-chromium biodegradable polymer Biolimus A9-eluting stent, MI = myocardial infarction, PCI = percutaneous coronary intervention, and SS-BP-BES = stainless steel biodegradable polymer Biolimus A9-eluting stent.
|
